Watch NGNE. Know when insiders buy.
One email the day a filing lands. Free.
NGNE
Neurogene Inc.
30.93
−1.64 −5.04%
USD · close Sep 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
42
WATCH · shorts 42
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $619MP/E —DIV YIELD —FCF YIELD -14.17%REV TTM —NET INCOME −$111.1MNET CASH —52W 16.37 – 42.84SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$36.7M | −$34.5M | — | -1.53 | −$23.8M | $354K | −$24.1M | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$33.3M | −$30.9M | — | -1.39 | −$26.1M | $281K | −$26.4M | Aug 11 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$27.5M | −$24.7M | — | -1.13 | −$17.4M | $128K | −$17.6M | Mar 24 |
| Q3 2025 · Sep 30 | $0 | — | — | −$23.8M | −$21M | — | -0.99 | −$19.5M | $127K | −$19.6M | Nov 13 |
| Q2 2025 · Jun 30 | $0 | −100.0% | — | −$26.1M | −$22M | — | -1.05 | −$19.5M | $148K | −$19.6M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$25.9M | −$22.6M | — | -1.08 | −$20.8M | $780K | −$21.6M | Aug 11 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$21.5M | −$19.5M | −918.9% | -0.99 | −$17.5M | $116K | −$17.6M | Mar 24 |
| Q3 2024 · Sep 30 | $0 | — | — | −$22.2M | −$20.2M | — | -1.19 | −$15.6M | $167K | −$15.7M | Nov 13 |
| Q2 2024 · Jun 30 | $925K | — | — | −$20.1M | −$18.5M | — | -1.09 | −$15.9M | $460K | −$16.4M | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$18.8M | −$16.9M | — | -1.00 | −$21.6M | $65K | −$21.7M | Nov 13 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$14.7M | $2.4M | — | — | −$17M | $128K | −$17.1M | Mar 24 |
| Q3 2023 · Sep 30 | $0 | — | — | −$15.2M | −$14.6M | — | -32.67 | −$11.6M | $82K | −$11.7M | Nov 18 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$103.3M | −$90.4M | — | -4.24 | −$77.2M | $1.2M | −$78.4M | — | — |
| FY2024 · to Dec 31 | $925K | — | −$82.6M | −$75.1M | -8123.7% | -4.28 | −$70.6M | $808K | −$71.4M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$55.6M | −$36.3M | — | — | −$51.4M | $321K | −$51.7M | — | — |
| FY2022 · to Dec 31 | — | — | −$56.5M | −$55.2M | — | -1.04 | −$52.8M | $2.2M | −$55.1M | — | — |
| FY2021 · to Dec 31 | — | — | −$60.7M | −$60.7M | — | -1.10 | −$47.6M | $3.3M | −$50.8M | — | — |
| FY2020 · to Dec 31 | — | — | −$33.7M | −$33.3M | — | -0.64 | −$24.6M | $2.2M | −$26.8M | — | — |
Every number comes from Neurogene Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.